This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Childs, R. W. Articles by Barrett, J. Search for Related Content PubMed PubMed Citation Articles by Childs, R. W. Articles by Barrett, J. Social Bookmarking                            What's this?

Successful Treatment of Metastatic Renal Cell Carcinoma With a Nonmyeloablative Allogeneic Peripheral-Blood Progenitor-Cell Transplant: Evidence for a Graft-Versus-Tumor Effect

From the Bone Marrow Transplant Unit, Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD.

Address reprint requests to Richard W. Childs, MD, Hematology Branch, Building 10, Room 7C103, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892; email childsr{at}nih.gov

PURPOSE: A 50-year-old man developed progressive pulmonary metastasis resistant to interferon alfa-2b treatment 7 months after he underwent left nephrectomy for stage III renal cell carcinoma. We performed a nonmyeloablative allogeneic peripheral-blood stem-cell transplant in this patient to exploit a possible graft-versus-tumor effect from allogeneic lymphocytes.

MATERIALS AND METHODS: The conditioning regimen consisted of fludarabine and cyclophosphamide followed by a T-cell replete, granulocyte-colony stimulating-factor–mobilized peripheral-blood stem-cell transplant from his HLA-identical brother. Cyclosporine was administered from days –4 to +45 to prevent graft rejection and acute graft-versus-host disease (GVHD).

RESULTS: Serial polymerase chain reaction analysis of hematopoietic lineage-specific minisatellites initiallyshowed mixed chimerism in CD14⁺ and CD15⁺ myeloid cells, CD3⁺ T cells, and CD34⁺ progenitor cells, with rapid conversion to 100% donor T-cell chimerism by day +60 and 100% donor myeloid cells by day +100. Serial computed tomography scans of the chest showed stable disease at day +30, slight regression of pulmonary lesions at day +63, and complete disappearance of all pulmonary metastatic disease by day +110. Mild transient acute GVHD disease of the skin occurred on day +60 and limited chronic GVHD of the skin occurred by day +200.

CONCLUSION: The complete regression of metastatic disease, which has now been maintained for more than 1 year, is compatible with a graft-versus-tumor effect.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Ishiyama, A. Takami, S. Suzuki, H. Konaka, M. Namiki, A. Ooi, and S. Nakao Relationship Between Tumor-infiltrating T Lymphocytes and Clinical Response After Reduced-intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Renal Cell Carcinoma: A Single Center Prospective Study Jpn. J. Clin. Oncol., September 20, 2009; (2009) hyp104v1. [Abstract] [Full Text] [PDF]

				S. Mackinnon Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation ASCO Educational Book, January 1, 2008; 2008(1): 334 - 337. [Abstract] [Full Text] [PDF]

				A. M. Carella and M. Bregni Current role of allogeneic stem cell transplantation in breast cancer Ann. Onc., October 1, 2007; 18(10): 1591 - 1593. [Full Text] [PDF]

				H. J. Deeg, M. O'Donnell, J. Tolar, R. Agarwal, R. E. Harris, S. A. Feig, M. C. Territo, R. H. Collins, P. A. McSweeney, E. A. Copelan, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy Blood, September 1, 2006; 108(5): 1485 - 1491. [Abstract] [Full Text] [PDF]

				E. Koscielniak, U. Gross-Wieltsch, J. Treuner, P. Winkler, T. Klingebiel, P. Lang, P. Bader, D. Niethammer, and R. Handgretinger Graft-Versus-Ewing Sarcoma Effect and Long-Term Remission Induced by Haploidentical Stem-Cell Transplantation in a Patient With Relapse of Metastatic Disease J. Clin. Oncol., January 1, 2005; 23(1): 242 - 244. [Full Text] [PDF]

				Y. Takahashi and R. W. Childs Nonmyeloablative Transplantation: An Allogeneic-Based Immunotherapy for Renal Cell Carcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6353S - 6359S. [Abstract] [Full Text] [PDF]

				M. Zoller Tumor Vaccination after Allogeneic Bone Marrow Cell Reconstitution of the Nonmyeloablatively Conditioned Tumor-Bearing Murine Host J. Immunol., December 15, 2003; 171(12): 6941 - 6953. [Abstract] [Full Text] [PDF]

				N. T. Ueno, Y. C. Cheng, G. Rondon, N. M. Tannir, J. L. Gajewski, D. R. Couriel, C. Hosing, M. J. de Lima, P. Anderlini, I. F. Khouri, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors Blood, November 15, 2003; 102(10): 3829 - 3836. [Abstract] [Full Text] [PDF]

				U. Jung, J. E. Foley, A. A. Erdmann, M. A. Eckhaus, and D. H. Fowler CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects Blood, November 1, 2003; 102(9): 3439 - 3446. [Abstract] [Full Text] [PDF]

				R. F. Storb, G. Lucarelli, P. A. McSweeney, and R. W. Childs Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors Hematology, January 1, 2003; 2003(1): 372 - 397. [Abstract] [Full Text] [PDF]

				S. Hummel, D. Wilms, M. Vitacolonna, and M. Zoller Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host J. Leukoc. Biol., November 1, 2002; 72(5): 898 - 912. [Abstract] [Full Text] [PDF]

				B. I. Rini, T. Zimmerman, W. M. Stadler, T. F. Gajewski, and N. J. Vogelzang Allogeneic Stem-Cell Transplantation of Renal Cell Cancer After Nonmyeloablative Chemotherapy: Feasibility, Engraftment, and Clinical Results J. Clin. Oncol., April 15, 2002; 20(8): 2017 - 2024. [Abstract] [Full Text] [PDF]

				F. Weissinger, B. M. Sandmaier, D. G. Maloney, W. I. Bensinger, T. Gooley, and R. Storb Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings Blood, December 15, 2001; 98(13): 3584 - 3588. [Abstract] [Full Text] [PDF]

				P. Tiberghien, C. Ferrand, B. Lioure, N. Milpied, R. Angonin, E. Deconinck, J.-M. Certoux, E. Robinet, P. Saas, B. Petracca, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft Blood, January 1, 2001; 97(1): 63 - 72. [Abstract] [Full Text] [PDF]

				R. Childs, A. Chernoff, N. Contentin, E. Bahceci, D. Schrump, S. Leitman, E. J. Read, J. Tisdale, C. Dunbar, W. M. Linehan, et al. Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation N. Engl. J. Med., September 14, 2000; 343(11): 750 - 758. [Abstract] [Full Text] [PDF]

				R. Childs, E. Clave, N. Contentin, D. Jayasekera, N. Hensel, S. Leitman, E.J. Read, C. Carter, E. Bahceci, N.S. Young, et al. Engraftment Kinetics After Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation: Full Donor T-Cell Chimerism Precedes Alloimmune Responses Blood, November 1, 1999; 94(9): 3234 - 3241. [Abstract] [Full Text] [PDF]